key: cord-0868151-0faitr7v authors: Tonelli, Roberto; Iattoni, Andrea; Girardis, Massimo; De Pietri, Lesley; Clini, Enrico; Mussini, Cristina title: Never Give Up: lesson learned from a severe COVID-19 patient. date: 2020-04-27 journal: Pulmonology DOI: 10.1016/j.pulmoe.2020.04.012 sha: 043ba8762d8429db88a10d5358ca09cf08976496 doc_id: 868151 cord_uid: 0faitr7v nan J o u r n a l P r e -p r o o f COVID-19 pandemic is causing major health consequences in affected persons needing hospital admission. Since the first epidemic outbreak in China we have learned that several factors including older age, comorbidities and individual immunological responses to infection may differently address the risk of disease progression and outcome (1) . Moreover, there is now quite a unanimous consensus that mortality rate of critically ill patients with SARS-CoV2 pneumonia admitted to Intensive Care Unit (ICU) is really considerable (2) and even a slightly higher than that recorded in patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) (3) . Different attempts using experimental anti-viral (4) and/or systemic anti-inflammatory drugs (5, 6) have been made to counteract both disease progression and fatal prognosis. Meanwhile, an expert opinion-based document was launched in order to address the early management-related actions for the individual patient, including the choice of an appropriate setting of care and the timing for non-invasive (NIV) or invasive mechanical ventilation (MV) (7) . In light of this, we here report the clinical course of a 72-year old Caucasian male (M.A.) admitted for SARS-CoV2 pneumonia at our University Hospital in Modena on last March 5 th . A multidisciplinary medical staff composed of different specialists (infectious diseases, pulmonology, intensive care) was in charge of care and assuming shared clinical decisions. Past medical history was characterized by limited atherosclerosis, systemic arterial hypertension, and stable chronic B-cell lymphocytic leukemia (LLC) only requiring periodic follow-up. Onset of symptoms was reported 6 days before admission and infection by SARS-CoV-2 was confirmed by RT-PCR swab nasal/throat samples on the day of admission. Patient presented with fever (38°C), dry cough, tachypnea (respiratory rate-RR= 24 bpm) and mild respiratory failure (PaO2/FiO2 242 breathing room air). Figure 1 shows the chest-X-ray and the lung ultrasound pattern on admission (day 1). Given the neurological and hemodynamic stability (Subsequent Organ Failure Assessment-SOFA score was 1) he was admitted to the Infectious Disease Unit where oxygen supply through nasal cannula at the flow of 2 L/min and antiviral therapy with darunavir/cobicistat was started in addition to hydroxychloroquine and azithromycin according to our local recommendations. Blood C-reactive Protein (CRP 7.8 mg/dl) was high whereas white blood cell-WBC count (62.510/ml) was abnormally increased also due to his LLC condition. On day 4, patient experienced a major respiratory worsening (PaO2/FiO2 105), with RR >40 bpm) despite oxygen supply at FiO2 60%). A multidisciplinary staff evaluation was conducted to balance the need for immediate endotracheal intubation (ETI) and MV with the potential risks derived from his hematological comorbidity. Decision was taken for a non-ICU care approach thus NIV in pressure support mode was started with the aim to target a pulse oximetry level >90% and a RR <30 bpm. At the same time, other antiinflammatory drugs for off-label therapeutic indication were not available in the hospital pharmacy. Third, it should be noted that, as tocilizumab was not available to prompt a potentially antiinflammatory drug effect, even in a later stage as was the case of our patient (see figure 2) , the choice to use NIV was indeed the only means to "buy time" before any upgraded decision of care could be taken. This highlights the role that noninvasive respiratory support may have during COVID-19 epidemic, which is not only to manage the advanced hypoxic respiratory failure (7), but also to help clinicians to assist a very severely ill patient even if at high risk. Ongoing data on this epidemic are showing that the decision to prevent endotracheal intubation by NIV might be a safe option for patients. While we are waiting for more convincing data on the role of anti-inflammatory agents to early brake systemic inflammation and progression of the disease (6,11), it has been discussed whether or not early ETI and MV would be the best option for the COVID-19 patient's outcome (12). One of the hypotheses behind this is that COVID-19 is not a typical ARDS, so MV in many cases is not the right treatment. COVID-19 patients show significant vasoconstriction of small blood vessels compared to the healthy and ARDS patients. It is known that ventilation reduces the small blood vessel size, meaning it is probably making things worse for most COVID-19 patients. Notably, a very recent audit in UK in over 6.000 patients shows that death rate in COVID-19 patients using advanced respiratory support (ETI, MV, ECMO) is significantly higher as compared with patients on basic support (oxygen with inspiratory fraction >50%, CPAP/BIPAP) (66.3 vs 51.6%, respectively). This in turn expresses a much higher risk rate when compared to that (22%) occurring in a retrospective series of hospitalized non-COVID viral pneumonia (13) . Finally, present experience has led clinicians to the evidence that such a very severe situation with difficult and risky decisions unavoidably lead the patient to a long clinical course with associated disability (14) . Since beating the virus is just the beginning, any lack of access to early physiotherapy and to a long-term strategy for survivors of severe COVID-19 is a problem to be overcome urgently (15) . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy Compassionate Use of Remdesivir for Patients with Severe Covid-19 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Effective Treatment of Severe COVID-19 Patients with Tocilizumab Early consensus management for non-ICU ARF SARS-CoV-2 emergency in Italy: from ward to trenches COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal A framework for rationing ventilators and critical care beds during the COVID-19 pandemic Potential Legal Liability for Withdrawing or Withholding Ventilators During COVID-19 Report of an ad-hoc international Task Force to develop an expert-based opinion on early and short-term rehabilitative interventions (after the acute hospital setting) in COVID-19 survivors. ERS website Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR). Monaldi Arch Chest Dis We want to thanks Professional Editor Colin Woodham for language editing. The authors have no conflicts of interest to declare.